- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03775265
Quimiorradioterapia com ou sem atezolizumabe no tratamento de pacientes com câncer de bexiga invasivo muscular localizado
Ensaio randomizado de fase III de quimiorradioterapia concomitante com ou sem atezolizumabe em câncer de bexiga invasivo muscular localizado
This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
- Outro: Quality-of-Life Assessment
- Medicamento: Cisplatin
- Medicamento: Fluorouracil
- Medicamento: Gemcitabine
- Medicamento: Atezolizumab
- Procedimento: Cystoscopy
- Medicamento: Mitomycin
- Outro: Survey Administration
- Procedimento: Biopsy of Bladder
- Procedimento: Computed Tomography
- Procedimento: Magnetic Resonance Imaging
- Radiação: Radiation Therapy
- Procedimento: Transurethral Resection of Bladder Tumor
Descrição detalhada
PRIMARY OBJECTIVE:
I. To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).
SECONDARY OBJECTIVES:
I. To compare overall survival between the two arms. II. To compare modified bladder intact event-free survival including cancer related death between arms.
III. To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.
IV. To estimate metastases-free survival by arm. V. To compare the qualitative and quantitative adverse events from each arm. VI. To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.
VII. To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.
VIII. To compare mean patient-reported global quality of life (QOL) at week 54 using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus (vs.) without atezolizumab.
TRANSLATIONAL MEDICINE OBJECTIVES:
I. To test the hypothesis that a panel of validated biomarkers of concurrent CRT involving nuclear MRE11, impaired deoxyribonucleic acid damage response (DDR) function and tumor subtyping will be prognostic for BI-EFS among patients receiving either concurrent CRT or chemoimmuno-radiotherapy (CIRT) of the primary tumor.
II. To test the hypothesis that tumor total mutation burden, neoantigen burden, infiltrating immune response, PD-L1 expression and T cell response are associated with augmented response after concurrent CIRT.
III. To bank urine specimens for future use.
PATIENT-REPORTED OUTCOMES (PROs) OBJECTIVES:
I. To compare mean patient-reported global QOL as measured by the EORTC QLQ-C30 Global Health Status subscale scores at week 54 between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with vs. without atezolizumab. (Primary) II. To compare mean patient-reported bowel symptoms at each assessment time by arm using the Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment from the Expanded Prostate Index, the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-Muscle Invasive Bladder Cancer (BLM30), the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EuroQol Five Dimension Five Level Scale (EQ-5D-5L). (Exploratory) III. To compare longitudinal change over time by arm in patient-reported global QOL using the EORTC QLQ-C30, the Bowel Domain of the Expanded Prostate Index (EPIC Bowel Assessment), the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-BLM30, the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EQ-5D-5L. (Exploratory)
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo radiation therapy (RT) (3 dimensional [D] CRT or intensity-modulated radiation therapy [IMRT]) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine intravenously (IV) twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a transurethral resection of bladder tumor (TURBT) at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and computed tomography (CT) or magnetic resonance imaging (MRI) at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
ARM II: Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6 months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5.
After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85054
- Mayo Clinic Hospital in Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Mayo Clinic in Arizona
-
Tucson, Arizona, Estados Unidos, 85719
- Banner University Medical Center - Tucson
-
Tucson, Arizona, Estados Unidos, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Auburn, California, Estados Unidos, 95602
- Sutter Auburn Faith Hospital
-
Auburn, California, Estados Unidos, 95603
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Berkeley, California, Estados Unidos, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Carmichael, California, Estados Unidos, 95608
- Mercy San Juan Medical Center
-
Carmichael, California, Estados Unidos, 95608
- Mercy Cancer Center - Carmichael
-
Elk Grove, California, Estados Unidos, 95758
- Mercy Cancer Center - Elk Grove
-
La Jolla, California, Estados Unidos, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Estados Unidos, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles General Medical Center
-
Marysville, California, Estados Unidos, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Estados Unidos, 95355
- Memorial Medical Center
-
Orange, California, Estados Unidos, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Palo Alto, California, Estados Unidos, 94301
- Palo Alto Medical Foundation Health Care
-
Rocklin, California, Estados Unidos, 95765
- Mercy Cancer Center - Rocklin
-
Roseville, California, Estados Unidos, 95661
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Roseville, California, Estados Unidos, 95661
- Sutter Roseville Medical Center
-
Sacramento, California, Estados Unidos, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
Sacramento, California, Estados Unidos, 95816
- Mercy Cancer Center - Sacramento
-
San Luis Obispo, California, Estados Unidos, 93401
- Pacific Central Coast Health Center-San Luis Obispo
-
Sunnyvale, California, Estados Unidos, 94086
- Palo Alto Medical Foundation-Sunnyvale
-
Woodland, California, Estados Unidos, 95695
- Woodland Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, Estados Unidos, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, Estados Unidos, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Estados Unidos, 80920
- Memorial Hospital North
-
Edwards, Colorado, Estados Unidos, 81632
- Shaw Cancer Center
-
Fort Collins, Colorado, Estados Unidos, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Estados Unidos, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Estados Unidos, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, Estados Unidos, 80631
- Banner North Colorado Medical Center
-
Loveland, Colorado, Estados Unidos, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, Estados Unidos, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
-
Connecticut
-
Greenwich, Connecticut, Estados Unidos, 06830
- Smilow Cancer Hospital Care Center at Greenwich
-
Guilford, Connecticut, Estados Unidos, 06437
- Smilow Cancer Hospital Care Center - Guilford
-
Hartford, Connecticut, Estados Unidos, 06102
- Hartford Hospital
-
Meriden, Connecticut, Estados Unidos, 06451
- Midstate Medical Center
-
New Britain, Connecticut, Estados Unidos, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Estados Unidos, 06520
- Yale University
-
North Haven, Connecticut, Estados Unidos, 06473
- Yale-New Haven Hospital North Haven Medical Center
-
Trumbull, Connecticut, Estados Unidos, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
Waterford, Connecticut, Estados Unidos, 06385
- Smilow Cancer Hospital Care Center - Waterford
-
-
Delaware
-
Millville, Delaware, Estados Unidos, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Estados Unidos, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Estados Unidos, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Estados Unidos, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20016
- Sibley Memorial Hospital
-
-
Florida
-
Aventura, Florida, Estados Unidos, 33180
- Mount Sinai Comprehensive Cancer Center at Aventura
-
Coral Gables, Florida, Estados Unidos, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Estados Unidos, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Gainesville, Florida, Estados Unidos, 32610
- UF Health Cancer Institute - Gainesville
-
Miami, Florida, Estados Unidos, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Medical Center
-
N. Venice, Florida, Estados Unidos, 34275
- Sarasota Memorial Hospital-Venice
-
Sarasota, Florida, Estados Unidos, 34239
- Sarasota Memorial Hospital
-
Sarasota, Florida, Estados Unidos, 34232
- Florida Cancer Specialists - Sarasota
-
Sarasota, Florida, Estados Unidos, 34239
- First Physicians Group - Urology Robotic and Minimally Invasive Surgery
-
Sarasota, Florida, Estados Unidos, 34243
- Sarasota Memorial Health Care Center at University Parkway
-
Sarasota, Florida, Estados Unidos, 34239
- Florida Cancer Specialists - Sarasota Downtown
-
Tampa, Florida, Estados Unidos, 33612
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30308
- Emory University Hospital Midtown
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Estados Unidos, 30342
- Emory Saint Joseph's Hospital
-
Newnan, Georgia, Estados Unidos, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Estados Unidos, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Estados Unidos, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Estados Unidos, 96813
- Queen's Cancer Cenrer - POB I
-
Honolulu, Hawaii, Estados Unidos, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Estados Unidos, 96817
- Queen's Cancer Center - Kuakini
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Hawaii Cancer Care - Westridge
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Pali Momi Medical Center
-
‘Aiea, Hawaii, Estados Unidos, 96701
- The Cancer Center of Hawaii-Pali Momi
-
-
Illinois
-
Barrington, Illinois, Estados Unidos, 60010
- Advocate Good Shepherd Hospital
-
Bloomington, Illinois, Estados Unidos, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, Estados Unidos, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, Estados Unidos, 62321
- Illinois CancerCare-Carthage
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern University
-
Chicago, Illinois, Estados Unidos, 60657
- Advocate Illinois Masonic Medical Center
-
Chicago, Illinois, Estados Unidos, 60612
- Rush MD Anderson Cancer Center
-
Crystal Lake, Illinois, Estados Unidos, 60014
- AMG Crystal Lake - Oncology
-
DeKalb, Illinois, Estados Unidos, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Estados Unidos, 62526
- Decatur Memorial Hospital
-
Downers Grove, Illinois, Estados Unidos, 60515
- Advocate Good Samaritan Hospital
-
Effingham, Illinois, Estados Unidos, 62401
- Crossroads Cancer Center
-
Elgin, Illinois, Estados Unidos, 60123
- Advocate Sherman Hospital
-
Elmhurst, Illinois, Estados Unidos, 60126
- Elmhurst Memorial Hospital
-
Eureka, Illinois, Estados Unidos, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, Estados Unidos, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, Estados Unidos, 61401
- Western Illinois Cancer Treatment Center
-
Galesburg, Illinois, Estados Unidos, 61401
- Illinois CancerCare-Galesburg
-
Geneva, Illinois, Estados Unidos, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Estados Unidos, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Hazel Crest, Illinois, Estados Unidos, 60429
- Advocate South Suburban Hospital
-
Highland Park, Illinois, Estados Unidos, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Hines, Illinois, Estados Unidos, 60141
- Edward Hines Jr VA Hospital
-
Kewanee, Illinois, Estados Unidos, 61443
- Illinois CancerCare-Kewanee Clinic
-
Libertyville, Illinois, Estados Unidos, 60048
- Condell Memorial Hospital
-
Libertyville, Illinois, Estados Unidos, 60048
- AMG Libertyville - Oncology
-
Macomb, Illinois, Estados Unidos, 61455
- Illinois CancerCare-Macomb
-
Maywood, Illinois, Estados Unidos, 60153
- Loyola University Medical Center
-
Naperville, Illinois, Estados Unidos, 60540
- Edward Hospital/Cancer Center
-
Oak Lawn, Illinois, Estados Unidos, 60453-2699
- Advocate Christ Medical Center
-
Ottawa, Illinois, Estados Unidos, 61350
- Illinois CancerCare-Ottawa Clinic
-
Park Ridge, Illinois, Estados Unidos, 60068
- Advocate Lutheran General Hospital
-
Pekin, Illinois, Estados Unidos, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, Estados Unidos, 61636
- Methodist Medical Center of Illinois
-
Peoria, Illinois, Estados Unidos, 61637
- OSF Saint Francis Medical Center
-
Peoria, Illinois, Estados Unidos, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, Estados Unidos, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, Estados Unidos, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield Clinic
-
Springfield, Illinois, Estados Unidos, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Estados Unidos, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Estados Unidos, 60555
- Northwestern Medicine Cancer Center Warrenville
-
Washington, Illinois, Estados Unidos, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, Estados Unidos, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, Estados Unidos, 46256
- Community Cancer Center North
-
Richmond, Indiana, Estados Unidos, 47374
- Reid Health
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Estados Unidos, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Estados Unidos, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Estados Unidos, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Estados Unidos, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Estados Unidos, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
West Des Moines, Iowa, Estados Unidos, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Estados Unidos, 66210
- University of Kansas Cancer Center-Overland Park
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, Estados Unidos, 67214
- Ascension Via Christi Hospitals Wichita
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Estados Unidos, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Estados Unidos, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
Louisville, Kentucky, Estados Unidos, 40207
- Baptist Health Louisville
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Louisiana Hematology Oncology Associates LLC
-
Baton Rouge, Louisiana, Estados Unidos, 70809
- Mary Bird Perkins Cancer Center
-
Metairie, Louisiana, Estados Unidos, 70006
- East Jefferson General Hospital
-
Metairie, Louisiana, Estados Unidos, 70006
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
New Orleans, Louisiana, Estados Unidos, 70112
- University Medical Center New Orleans
-
-
Maine
-
Bath, Maine, Estados Unidos, 04530
- MaineHealth Coastal Cancer Treatment Center
-
Belfast, Maine, Estados Unidos, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, Estados Unidos, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Norway, Maine, Estados Unidos, 04268
- MaineHealth Stephens Hospital
-
Portland, Maine, Estados Unidos, 04102
- MaineHealth Maine Medical Center - Portland
-
Rockport, Maine, Estados Unidos, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, Estados Unidos, 04073
- MaineHealth Cancer Care Center of York County
-
Sanford, Maine, Estados Unidos, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
Scarborough, Maine, Estados Unidos, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Estados Unidos, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, Estados Unidos, 02114
- Massachusetts General Hospital Cancer Center
-
Lowell, Massachusetts, Estados Unidos, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Rogel Cancer Center
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Battle Creek, Michigan, Estados Unidos, 49017
- Bronson Battle Creek
-
Brighton, Michigan, Estados Unidos, 48116
- University of Michigan - Brighton Center for Specialty Care
-
Brighton, Michigan, Estados Unidos, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Estados Unidos, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Estados Unidos, 48118
- Chelsea Hospital
-
Clarkston, Michigan, Estados Unidos, 48346
- Michigan Healthcare Professionals Clarkston
-
Dearborn, Michigan, Estados Unidos, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Estados Unidos, 48202
- Henry Ford Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48236
- Henry Ford Health Saint John Hospital
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Weisberg Cancer Treatment Center
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Michigan Healthcare Professionals Farmington
-
Farmington Hills, Michigan, Estados Unidos, 48336
- Corewell Health Farmington Hills Hospital
-
Kalamazoo, Michigan, Estados Unidos, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, Estados Unidos, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Macomb, Michigan, Estados Unidos, 48044
- Henry Ford Saint John Hospital - Macomb Medical
-
Madison Heights, Michigan, Estados Unidos, 48071
- Michigan Healthcare Professionals Madison Heights
-
Pontiac, Michigan, Estados Unidos, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Estados Unidos, 48341
- Michigan Healthcare Professionals Pontiac
-
Royal Oak, Michigan, Estados Unidos, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Estados Unidos, 48601
- MyMichigan Medical Center Saginaw
-
Traverse City, Michigan, Estados Unidos, 49684
- Munson Medical Center
-
Troy, Michigan, Estados Unidos, 48098
- Michigan Healthcare Professionals Troy
-
Troy, Michigan, Estados Unidos, 48085
- Corewell Health Beaumont Troy Hospital
-
Warren, Michigan, Estados Unidos, 48093
- Henry Ford Health Warren Hospital
-
West Bloomfield, Michigan, Estados Unidos, 48322
- Henry Ford West Bloomfield Hospital
-
Wyoming, Michigan, Estados Unidos, 49519
- University of Michigan Health - West
-
-
Minnesota
-
Bemidji, Minnesota, Estados Unidos, 56601
- Sanford Joe Lueken Cancer Center
-
Coon Rapids, Minnesota, Estados Unidos, 55433
- Mercy Hospital
-
Duluth, Minnesota, Estados Unidos, 55805
- Miller-Dwan Hospital
-
Edina, Minnesota, Estados Unidos, 55435
- Fairview Southdale Hospital
-
Fridley, Minnesota, Estados Unidos, 55432
- Unity Hospital
-
Monticello, Minnesota, Estados Unidos, 55362
- Monticello Cancer Center
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
Saint Cloud, Minnesota, Estados Unidos, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Regions Hospital
-
-
Missouri
-
Bonne Terre, Missouri, Estados Unidos, 63628
- Parkland Health Center-Bonne Terre
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Saint Francis Medical Center
-
City of Saint Peters, Missouri, Estados Unidos, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Estados Unidos, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Estados Unidos, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Estados Unidos, 64064
- University of Kansas Cancer Center - Lee's Summit
-
Saint Joseph, Missouri, Estados Unidos, 64506
- Heartland Regional Medical Center
-
Sainte Genevieve, Missouri, Estados Unidos, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Estados Unidos, 65807
- CoxHealth South Hospital
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Estados Unidos, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Estados Unidos, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Estados Unidos, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Estados Unidos, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Estados Unidos, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Billings, Montana, Estados Unidos, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, Estados Unidos, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, Estados Unidos, 59405
- Benefis Sletten Cancer Institute
-
-
Nebraska
-
Bellevue, Nebraska, Estados Unidos, 68123
- Nebraska Medicine-Bellevue
-
Kearney, Nebraska, Estados Unidos, 68847
- CHI Health Good Samaritan
-
Omaha, Nebraska, Estados Unidos, 68114
- Nebraska Methodist Hospital
-
Omaha, Nebraska, Estados Unidos, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Estados Unidos, 68118
- Nebraska Medicine-Village Pointe
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, Estados Unidos, 89106
- Radiation Oncology Centers of Nevada Central
-
Las Vegas, Nevada, Estados Unidos, 89119
- Radiation Oncology Centers of Nevada Southeast
-
Las Vegas, Nevada, Estados Unidos, 89128
- Comprehensive Cancer Centers of Nevada - Northwest
-
Las Vegas, Nevada, Estados Unidos, 89144
- Comprehensive Cancer Centers of Nevada - Town Center
-
Las Vegas, Nevada, Estados Unidos, 89148
- Comprehensive Cancer Centers of Nevada
-
Las Vegas, Nevada, Estados Unidos, 89169
- Comprehensive Cancer Centers of Nevada - Central Valley
-
Las Vegas, Nevada, Estados Unidos, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, Estados Unidos, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
Basking Ridge, New Jersey, Estados Unidos, 07920
- Memorial Sloan Kettering Basking Ridge
-
Camden, New Jersey, Estados Unidos, 08103
- Cooper Hospital University Medical Center
-
Hackensack, New Jersey, Estados Unidos, 07601
- Hackensack University Medical Center
-
Middletown, New Jersey, Estados Unidos, 07748
- Memorial Sloan Kettering Monmouth
-
Montvale, New Jersey, Estados Unidos, 07645
- Memorial Sloan Kettering Bergen
-
Voorhees Township, New Jersey, Estados Unidos, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New York
-
Commack, New York, Estados Unidos, 11725
- Memorial Sloan Kettering Commack
-
Harrison, New York, Estados Unidos, 10604
- Memorial Sloan Kettering Westchester
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Estados Unidos, 10065
- Memorial Sloan Kettering Cancer Center
-
Rochester, New York, Estados Unidos, 14642
- University of Rochester
-
Rochester, New York, Estados Unidos, 14620
- Highland Hospital
-
Sleepy Hollow, New York, Estados Unidos, 10591
- Phelps Memorial Hospital Center
-
Stony Brook, New York, Estados Unidos, 11794
- Stony Brook University Medical Center
-
Syracuse, New York, Estados Unidos, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Einstein Campus
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center - Moses Campus
-
The Bronx, New York, Estados Unidos, 10461
- Montefiore Medical Center-Weiler Hospital
-
Uniondale, New York, Estados Unidos, 11553
- Memorial Sloan Kettering Nassau
-
West Islip, New York, Estados Unidos, 11795
- Good Samaritan University Hospital
-
-
North Carolina
-
Hendersonville, North Carolina, Estados Unidos, 28791
- Margaret R Pardee Memorial Hospital
-
Kenansville, North Carolina, Estados Unidos, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, Estados Unidos, 28501
- ECU Health Oncology Kinston
-
Richlands, North Carolina, Estados Unidos, 28574
- ECU Health Oncology Richlands
-
-
North Dakota
-
Bismarck, North Dakota, Estados Unidos, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, Estados Unidos, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Estados Unidos, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Estados Unidos, 44109
- MetroHealth Medical Center
-
Columbus, Ohio, Estados Unidos, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, Estados Unidos, 45415
- Dayton Physician LLC - Englewood
-
Kettering, Ohio, Estados Unidos, 45429
- Kettering Medical Center
-
Kettering, Ohio, Estados Unidos, 45409
- Greater Dayton Cancer Center
-
West Chester, Ohio, Estados Unidos, 45069
- University of Cincinnati Cancer Center-West Chester
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Allentown, Pennsylvania, Estados Unidos, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Altoona, Pennsylvania, Estados Unidos, 16601
- UPMC Altoona
-
Beaver, Pennsylvania, Estados Unidos, 15009
- UPMC-Heritage Valley Health System Beaver
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Carlisle, Pennsylvania, Estados Unidos, 17015
- Carlisle Regional Cancer Center
-
Chadds Ford, Pennsylvania, Estados Unidos, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Estados Unidos, 17822
- Geisinger Medical Center
-
Erie, Pennsylvania, Estados Unidos, 16505
- UPMC Hillman Cancer Center Erie
-
Farrell, Pennsylvania, Estados Unidos, 16121
- UPMC Cancer Center at UPMC Horizon
-
Greensburg, Pennsylvania, Estados Unidos, 15601
- UPMC Cancer Centers - Arnold Palmer Pavilion
-
Harrisburg, Pennsylvania, Estados Unidos, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Hershey, Pennsylvania, Estados Unidos, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Johnstown, Pennsylvania, Estados Unidos, 15901
- UPMC-Johnstown/John P. Murtha Regional Cancer Center
-
Lewisburg, Pennsylvania, Estados Unidos, 17837
- Geisinger Medical Oncology-Lewisburg
-
McKeesport, Pennsylvania, Estados Unidos, 15132
- UPMC Cancer Center at UPMC McKeesport
-
Mechanicsburg, Pennsylvania, Estados Unidos, 17050
- UPMC Hillman Cancer Center at Rocco And Nancy Ortenzio Cancer Pavilion
-
Monroeville, Pennsylvania, Estados Unidos, 15146
- UPMC Cancer Center - Monroeville
-
Moon Township, Pennsylvania, Estados Unidos, 15108
- UPMC Hillman Cancer Center in Coraopolis
-
N. Huntingdon, Pennsylvania, Estados Unidos, 15642
- Arnold Palmer Cancer Center Medical Oncology Norwin
-
New Castle, Pennsylvania, Estados Unidos, 16105
- UPMC Hillman Cancer Center - New Castle
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15213
- UPMC-Magee Womens Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC-Shadyside Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15215
- UPMC-Saint Margaret
-
Pittsburgh, Pennsylvania, Estados Unidos, 15237
- UPMC-Passavant Hospital
-
Pittsburgh, Pennsylvania, Estados Unidos, 15243
- UPMC-Saint Clair Hospital Cancer Center
-
Seneca, Pennsylvania, Estados Unidos, 16346
- UPMC Cancer Center at UPMC Northwest
-
Uniontown, Pennsylvania, Estados Unidos, 15401
- UPMC Uniontown Hospital Radiation Oncology
-
Washington, Pennsylvania, Estados Unidos, 15301
- UPMC Washington Hospital Radiation Oncology
-
Wilkes-Barre, Pennsylvania, Estados Unidos, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
York, Pennsylvania, Estados Unidos, 17408
- UPMC Memorial
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Medical University of South Carolina
-
Greenville, South Carolina, Estados Unidos, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, Estados Unidos, 29615
- Prisma Health Cancer Institute - Eastside
-
Greer, South Carolina, Estados Unidos, 29650
- Prisma Health Cancer Institute - Greer
-
Greer, South Carolina, Estados Unidos, 29651
- Gibbs Cancer Center-Pelham
-
Myrtle Beach, South Carolina, Estados Unidos, 29577
- Carolina Regional Cancer Center
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Estados Unidos, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Estados Unidos, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Galveston, Texas, Estados Unidos, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, Estados Unidos, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- Michael E DeBakey VA Medical Center
-
Richardson, Texas, Estados Unidos, 75080
- UT Southwestern Clinical Center at Richardson/Plano
-
-
Vermont
-
Saint Johnsbury, Vermont, Estados Unidos, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Fishersville, Virginia, Estados Unidos, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
-
Washington
-
Auburn, Washington, Estados Unidos, 98001
- MultiCare Auburn Medical Center
-
Gig Harbor, Washington, Estados Unidos, 98335
- MultiCare Gig Harbor Medical Park
-
Kirkland, Washington, Estados Unidos, 98034
- FHCC at EvergreenHealth
-
Puyallup, Washington, Estados Unidos, 98372
- MultiCare Good Samaritan Hospital
-
Renton, Washington, Estados Unidos, 98055
- Valley Medical Center
-
Seattle, Washington, Estados Unidos, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Estados Unidos, 98109
- Fred Hutchinson Cancer Center
-
Silverdale, Washington, Estados Unidos, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Tacoma, Washington, Estados Unidos, 98405
- MultiCare Tacoma General Hospital
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26506
- West Virginia University Healthcare
-
-
Wisconsin
-
Antigo, Wisconsin, Estados Unidos, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, Estados Unidos, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, Estados Unidos, 54806
- Northwest Wisconsin Cancer Center
-
Burlington, Wisconsin, Estados Unidos, 53105
- Aurora Cancer Care-Southern Lakes VLCC
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Marshfield Medical Center-EC Cancer Center
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Mayo Clinic Health System-Eau Claire Clinic
-
Germantown, Wisconsin, Estados Unidos, 53022
- Aurora Health Care Germantown Health Center
-
Grafton, Wisconsin, Estados Unidos, 53024
- Aurora Cancer Care-Grafton
-
Green Bay, Wisconsin, Estados Unidos, 54311
- Aurora BayCare Medical Center
-
Green Bay, Wisconsin, Estados Unidos, 54301
- Bellin Memorial Hospital
-
Kenosha, Wisconsin, Estados Unidos, 53142
- Aurora Cancer Care-Kenosha South
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marinette, Wisconsin, Estados Unidos, 54143
- Aurora Bay Area Medical Group-Marinette
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, Estados Unidos, 54451
- Aspirus Medford Hospital
-
Milwaukee, Wisconsin, Estados Unidos, 53209
- Aurora Cancer Care-Milwaukee
-
Milwaukee, Wisconsin, Estados Unidos, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Estados Unidos, 53233
- Aurora Sinai Medical Center
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Marshfield Medical Center - Minocqua
-
New Richmond, Wisconsin, Estados Unidos, 54017
- Cancer Center of Western Wisconsin
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Oshkosh, Wisconsin, Estados Unidos, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, Estados Unidos, 53406
- Aurora Cancer Care-Racine
-
Racine, Wisconsin, Estados Unidos, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Marshfield Medical Center-Rice Lake
-
Sheboygan, Wisconsin, Estados Unidos, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Stevens Point, Wisconsin, Estados Unidos, 54481
- Aspirus Cancer Care - Stevens Point
-
Summit, Wisconsin, Estados Unidos, 53066
- Aurora Medical Center in Summit
-
Two Rivers, Wisconsin, Estados Unidos, 54241
- Vince Lombardi Cancer Clinic-Two Rivers
-
Wausau, Wisconsin, Estados Unidos, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, Estados Unidos, 53226
- Aurora Cancer Care-Milwaukee West
-
West Allis, Wisconsin, Estados Unidos, 53227
- Aurora West Allis Medical Center
-
Weston, Wisconsin, Estados Unidos, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, Estados Unidos, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
STEP 1 REGISTRATION: If this will be the first patient from a registering site to receive a given RT modality (3DCRT vs. IMRT), the site must first submit pre-RT planning documents within 3 days of Step 1 registration and receive approval from Imaging and Radiation Oncology Core (IROC) before randomizing the patient to Step 2. If this will not be the first patient to receive a specific RT modality, the patient should be immediately randomized to Step 2 on the same day.
-
STEP 2 RANDOMIZATION: If patient required review of pre-RT planning, randomization must occur within 14 days of initial registration.
-
Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 120 days prior to randomization and no intervening treatment between the histologic proof and randomization. Patients with mixed urothelial carcinoma will be eligible for the trial, but the presence of small cell carcinoma will make a patient ineligible. Patients with lymph nodes >= 1.0 cm in shortest cross-sectional diameter on imaging (computed tomography [CT]/magnetic resonance imaging [MRI] of abdomen and pelvis) must have a biopsy of the enlarged lymph node showing no tumor involvement within 70 days prior to randomization. These patients may be suitable for neoadjuvant chemotherapy and radical cystectomy and are eligible for this trial if they seek out a bladder sparing treatment strategy, however patients who have received prior systemic chemotherapy for bladder cancer are not eligible for the trial.
-
Patients must undergo a transurethral resection of bladder tumor (TURBT) within 70 days prior to randomization. In a situation where a patient is referred from outside to the enrolling institution, patient must have a repeat office cystoscopy by the urologist who will be following the patient on the clinical trial to assess the adequacy of the prior TURBT. This cystoscopy can be performed in urologist office without general anesthesia. Patient may then undergo repeat TURBT if deemed necessary as standard of care by the treating urologist. Patients may have either completely or partially resected tumors as long as the treating urologist attempted maximal resection. Patient must not have T4b disease
-
Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease. Eligibility is based on the local radiology report.
-
Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.
-
Patients must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within the previous 24 months except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract including renal pelvis and ureter if the patient had undergone complete nephroureterectomy.
-
Patients must not have diffuse CIS based on cystoscopy and biopsy.
-
Patient must be planning to receive one of the protocol specified chemotherapy regimens.
-
All adverse events associated with any prior surgery and intravesical therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to randomization.
-
Patient must not have received any systemic chemotherapy for their bladder cancer.
-
Patient must not have had prior pelvic radiation.
-
Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.
-
Patients must not have received any systemic therapy (including, but not limited to, interferon alfa-2b, high dose IL-2, pegylated interferon [PEG-IFN], anti-PD-1, anti-PD-L1), for non-muscle invasive bladder cancer. Prior intravesical bacillus Calmette-Guerin (BCG), interferon, and intravesical chemotherapy are allowed.
-
Patients must not have received any of the following prohibited therapies within 28 days prior to randomization or be planning to receive any of the following prohibited therapies during protocol treatment:
- Anti-cancer systemic chemotherapy or biological therapy not specified in the protocol.
- Immunotherapy not specified in this protocol.
- Systemic or intravesical use of any non-study anti-cancer agent (investigational or non-investigational).
- Investigational agents other than atezolizumab.
- Live vaccines: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist®) are live attenuated vaccines, and are not allowed. Prior administration of intravesical BCG is allowed.
- Glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology. The use of physiologic doses of corticosteroids (defined as 10 mg prednisone) are acceptable, however site investigators should consult with the study chair for any dose higher than 10 mg prednisone. Dexamethasone 4 mg IV with chemotherapy to prevent nausea is allowed.
- RANKL infusion: Concurrent denosumab (which binds the cytokine RANKL) for any known indication is prohibited due to interaction with study medication.
-
Patients must not have a major surgical procedure within 28 days prior to randomization. If patient had any surgical procedure then they should have recovered to full presurgical performance status and surgical adverse events should have resolved to grade =< 2. TURBT is not considered a major surgical procedure.
-
Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions:
- Patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Physiological doses equivalent of 10 mg prednisone daily are allowed. Short term steroids given as antiemetic therapy, e.g. 4 mg dexamethasone or equivalent once a week, is allowed.
-
Patients must not have received a live, attenuated vaccine within 4 weeks prior to randomization or anticipate that such a live, attenuated vaccine will be required while on protocol treatment and up to 5 months after the last dose of protocol treatment.
- Inactivated influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to randomization or while on protocol treatment and up to 5 months after the last dose of protocol treatment.
-
Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.
-
Patients must be >= 18 years of age
-
Patient may or may not be radical cystectomy candidates.
-
Absolute neutrophil count (ANC) >= 1,500/microliter (mcL) (within 28 days prior to randomization).
-
Platelets >= 100,000/mcL (within 28 days prior to randomization).
-
Hemoglobin >= 9 g/dL (within 28 days prior to randomization).
-
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 28 days prior to randomization).
-
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x IULN (within 28 days prior to randomization).
-
Patients must not have clinically significant liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).
-
Patients must have adequate renal function as evidenced by calculated creatinine clearance >= 25 mL/min. The creatinine used to calculate the clearance result must have been obtained within 28 days prior to randomization.
-
Patients must have Zubrod performance status =< 2.
-
Patients must have a baseline electrocardiography (ECG) performed within 30 days prior to randomization.
-
Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis.
-
Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to randomization. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are not eligible. If patient develops urinary tract infection after TURBT they must have recovered from the infection prior to registration.
-
Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, Graves' disease treated with methimazole or glomerulonephritis.
-
Patient must not have a history of active tuberculosis.
-
If patient has a known history of hepatitis B virus (HBV) or hepatitis C virus (HCV), they must meet the following criteria within 28 days prior to randomization.
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
-
Patients who are known to be positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:
- A stable regimen of highly active anti-retroviral therapy (HAART)
- No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections
- A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests within 28 days prior to randomization.
-
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
-
Female patients of childbearing potential must have a serum pregnancy test prior to randomization. Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment, and for 5 months (150 days) after the last dose of all study drugs. A woman is considered to be of "reproductive potential" if she has had a menses at any time in the preceding 12 consecutive months.
-
Patients must not be known to be allergic to Chinese hamster egg or ovary cell products and must not have any known major allergic reactions to any study drug.
-
Patients must be offered the opportunity to participate in specimen banking for future studies.
-
Patients who can complete Patient-Reported Outcome instruments in English or Spanish must agree to complete the EORTC QLQ-C30, the EORTC QLQ-BLM30, the EPIC Bowel Assessment, and the EQ-5D-5L per protocol schedule of assessment.
-
As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Arm I (RT, chemotherapy)
Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine IV twice weekly for 6 weeks concurrent with RT, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5. |
Ancillary studies
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo a cystoscopy
Outros nomes:
Given IV
Outros nomes:
Ancillary studies Undergo a bladder biopsy
Outros nomes:
Undergo CT or MRI
Outros nomes:
Undergo CT or MRI
Outros nomes:
Undergo 3DCRT or IMRT
Outros nomes:
Undergo a TURBT
Outros nomes:
|
|
Experimental: Arm II (RT, chemotherapy, atezolizumab)
Patients undergo RT (3DCRT or IMRT) daily Monday-Friday for up to 7-8 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 9 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo a TURBT with bladder biopsy at randomization and week 18 as well as cystoscopy at randomization, at weeks 18, 30, 42, 54, then every 3 months through year 2, followed by every 6months through year 5 and CT or MRI at randomization, at weeks 18, 30, 42, 54, then every 6 months through year 2, followed by every 12 months through year 5. |
Ancillary studies
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo a cystoscopy
Outros nomes:
Given IV
Outros nomes:
Ancillary studies Undergo a bladder biopsy
Outros nomes:
Undergo CT or MRI
Outros nomes:
Undergo CT or MRI
Outros nomes:
Undergo 3DCRT or IMRT
Outros nomes:
Undergo a TURBT
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Bladder intact event-free survival (BI-EFS)
Prazo: From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years
|
At each time point, futility will be evaluated, and in the latter two analyses, efficacy will also be evaluated as specified. The final BI-EFS intent-to-treat analysis will be conducted using a stratified logrank test stratifying on stratification factors, and testing treatment at the one-sided significance level of 0.022 to account for multiple interim testing. The hazard ratio (HR) will be estimated using a stratified Cox proportional hazards model and the 95% confidence interval (CI) for the HR will be provided. Results from an unstratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median BI-EFS for each treatment arm. |
From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sobrevivência específica do câncer
Prazo: Da data da randomização até a data da morte por câncer de bexiga, avaliada até 5 anos
|
Da data da randomização até a data da morte por câncer de bexiga, avaliada até 5 anos
|
|
|
Overall survival (OS)
Prazo: From date of randomization to death from any cause, assessed up to 5 years
|
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS. |
From date of randomization to death from any cause, assessed up to 5 years
|
|
Modified bladder intact event-free survival (mBI-EFS)
Prazo: From date of randomization to the first documentation of a mBI-EFS event, assessed within 90 days
|
Analysis of modified BI-EFS, i.e., a sensitivity analysis of BI-EFS, where bladder cancer event is defined as histologically proven presence of muscle invasive bladder cancer, clinical evidence of nodal or metastatic disease, radical cystectomy, or death within 90 days of receiving protocol specified treatment, will also be conducted. |
From date of randomization to the first documentation of a mBI-EFS event, assessed within 90 days
|
|
Biopsy response
Prazo: At 18 weeks
|
The Cochran-Mantel-Haenszel statistic will be used with modified ridit scores to evaluate the biopsy outcomes of complete response versus (vs.) down-staging vs. no response for the two treatment arms. |
At 18 weeks
|
|
Complete response duration
Prazo: From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed at 18 weeks
|
For the subset of patients who achieve a complete response during the week 18 biopsy window, complete response duration is defined from the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause. Will be analyzed using a similar method as for BI-EFS. |
From the date of the biopsy documenting the complete response to the time of muscle invasive recurrence, local progression, evidence of metastatic disease or death due to any cause, assessed at 18 weeks
|
|
Progression-free survival
Prazo: From date of randomization to first radiologic or histologic evidence of local progression, nodal or distant metastasis, or death due to any cause, assessed up to 5 years
|
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS. |
From date of randomization to first radiologic or histologic evidence of local progression, nodal or distant metastasis, or death due to any cause, assessed up to 5 years
|
|
Metastasis-free survival
Prazo: From date of randomization to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years
|
Will be estimated using Kaplan-Meier methodology for each treatment arm. Will be analyzed using a similar method as for BI-EFS. |
From date of randomization to first radiologic or histologic evidence of metastatic disease or death due to any cause, assessed up to 5 years
|
|
Quality of life
Prazo: Baseline up to 5 years
|
Assessed with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ)-C30. Will be examined using linear mixed models with patient considered as the random effect. The baseline physical function score and the stratification factors will be included in the regression model as adjustment covariates. |
Baseline up to 5 years
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Treatment interactions
Prazo: Up to 5 years
|
A Cox regression model will be used to evaluate the main effects of treatment arm and the main effect for each stratification factor and the interaction of the stratification factor with treatment in terms of both the primary endpoint and secondary endpoints. The stratification factors to be evaluated include: (1) clinical stage T2 vs. T3/T4a, (2) intended chemotherapy regimen cisplatin vs. 5-FU + mitomycin-C vs. gemcitabine, (3) radiation field small pelvis vs. bladder only and (4) performance status 0-1 vs. 2. There may be other radiation summary measures that may also be explored in terms of their modification of the experimental treatment effect including extent of radiation to lymph node fields. Subgroup analysis defined by stratification factors will also be conducted for primary endpoint and key secondary. |
Up to 5 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Parminder Singh, SWOG Cancer Research Network
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Urogenitais Masculinas
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Neoplasias Urológicas
- Doenças da Bexiga Urinária
- Neoplasias da Bexiga Urinária
- Produtos químicos orgânicos
- Compostos heterocíclicos, 1 anel
- Compostos heterocíclicos
- Compostos heterocíclicos, 2 anel
- Compostos heterocíclicos, anel fundido
- Técnicas de investigação
- Terapêutica
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Procedimentos cirúrgicos, operatórios
- Procedimentos cirúrgicos minimamente invasivos
- Fenômenos físicos
- Indoles
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Desoxicitidina
- Citidina
- Nucleosídeos de pirimidina
- Pirimidinas
- Elementos
- Metais
- Técnicas de diagnóstico, cirúrgico
- Endoscopia
- Técnicas de química, analíticas
- Análise de espectro
- Uracil
- Pirimidinonas
- Metais, pesados
- Compostos de platina
- Quinonas
- Elementos de transição
- Azirines
- Procedimentos cirúrgicos urológicos
- Procedimentos cirúrgicos urogenitais
- Técnicas de diagnóstico, urológico
- Mitomicinas
- Indolequinonas
- Gemcitabina
- Fluorouracila
- Cisplatina
- Mitomicina
- Citrato de 1,2-diaminociclohexanoplatina II
- Radioterapia
- Radiação
- Espectroscopia de ressonância magnética
- Platina
- Ressecção transuretral da bexiga
- Atezolizumab
- DeHyDroftorafur
- Cistoscopia
- Mitozytrex
Outros números de identificação do estudo
- NCI-2018-03264
- U10CA180888 (Concessão/Contrato do NIH dos EUA)
- NCI-2018-03264 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- S1806 (Outro identificador: CTEP)
- S1806 (Outro identificador: SWOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .